Proto-Oncogene Proteins c-ret
"Proto-Oncogene Proteins c-ret" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Receptor protein-tyrosine kinases involved in the signaling of GLIAL CELL-LINE DERIVED NEUROTROPHIC FACTOR ligands. They contain an extracellular cadherin domain and form a receptor complexes with GDNF RECEPTORS. Mutations in ret protein are responsible for HIRSCHSPRUNG DISEASE and MULTIPLE ENDOCRINE NEOPLASIA TYPE 2.
| Descriptor ID |
D051096
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.087 D12.776.395.550.200.188.500 D12.776.543.131.500 D12.776.543.750.630.217 D12.776.624.664.700.194
|
| Concept/Terms |
Proto-Oncogene Proteins c-ret- Proto-Oncogene Proteins c-ret
- Proto Oncogene Proteins c ret
- c-ret, Proto-Oncogene Proteins
- Receptor Tyrosine Kinase RET
- ret Proto-Oncogene Proteins
- Proto-Oncogene Proteins, ret
- ret Proto Oncogene Proteins
- Proto-Oncogene Protein c-ret
- Proto Oncogene Protein c ret
- c-ret, Proto-Oncogene Protein
- c-ret Protein
- Proto-Oncogene Protein Ret
- Proto Oncogene Protein Ret
- Ret, Proto-Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-ret".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-ret".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-ret" by people in this website by year, and whether "Proto-Oncogene Proteins c-ret" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-ret" by people in Profiles.
-
Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence. J Clin Endocrinol Metab. 2024 Oct 15; 109(11):2729-2734.
-
Population-Based Genomic RET Screening-Reply. JAMA Otolaryngol Head Neck Surg. 2023 09 01; 149(9):853.
-
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series. Clin Lung Cancer. 2023 11; 24(7):666-671.
-
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. J Thorac Oncol. 2022 09; 17(9):1130-1136.
-
RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer. J Thorac Oncol. 2021 05; 16(5):798-806.
-
RET rearrangements are actionable alterations in breast cancer. Nat Commun. 2018 11 16; 9(1):4821.
-
FRMD4A/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma. J Thorac Oncol. 2017 02; 12(2):e15-e16.
-
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15; 122(24):3856-3864.
-
Management of hereditary medullary thyroid carcinoma. Endocrine. 2016 Jul; 53(1):7-17.
-
Genetic screening of patients with medullary thyroid cancer in a referral center in Greece during the past two decades. Eur J Endocrinol. 2015 Apr; 172(4):501-9.